Results 21 to 30 of about 3,893,535 (160)

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Frontiers in Medicine, 2022
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR)
Mengqi Shi, Mengqi Shi, Vivianne Jakobsson, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Pek-Lan Khong, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang, Jingjing Zhang, Jingjing Zhang   +15 more
doaj   +1 more source

Lutathera^®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Pharmaceuticals, 2019
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.
Ute Hennrich, Klaus Kopka
doaj   +1 more source

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review

EJNMMI Research, 2018
Background The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation.
Daphne Merel Valerie Huizing, Berlinda Jantina de Wit-van der Veen, Marcel Verheij, Marcellus Petrus Maria Stokkel   +3 more
doaj   +1 more source

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

Clinical and Translational Radiation Oncology, 2020
Background: The combination of somatostatin receptor-directed peptide receptor radionuclide therapy (PRRT) in combination with external beam radiotherapy (EBRT) might prove a feasible treatment option in patients with advanced meningioma.
Philipp E. Hartrampf, Heribert Hänscheid, Olivia Kertels, Andreas Schirbel, Michael C. Kreissl, Michael Flentje, Reinhart A. Sweeney, Andreas K. Buck, Bülent Polat, Constantin Lapa   +9 more
doaj   +1 more source

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

, 2021
Peptide receptor radionuclide therapy (PRRT) consists of the administration of a tumor-targeting radiopharmaceutical into the circulation of a patient. The radiopharmaceutical will bind to a specific peptide receptor leading to tumor-specific binding and
Van Cutsem, Eric, Jeroen Dekervel, Dekervel, Jeroen, Eric Van Cutsem, Kristof Baete, Deroose, Christophe M., Baete, Kristof, Kristiaan Nackaerts, Paul Clement, Niloefar Ahmadi Bidakhvidi, Verslype, Chris, Christophe M. Deroose, Clement, Paul, Ahmadi Bidakhvidi, Niloefar, Karolien Goffin, Chris Verslype, Goffin, Karolien, Nackaerts, Kristiaan   +17 more
core   +1 more source

Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy

EJNMMI Research, 2022
Background Somatostatin receptor 68Ga PET imaging is standard for evaluation of a patient’s suitability for 177Lu peptide receptor radionuclide therapy of neuroendocrine tumours (NETs).
Anna Stenvall, Johan Gustafsson, Erik Larsson, Daniel Roth, Anna Sundlöv, Lena Jönsson, Cecilia Hindorf, Tomas Ohlsson, Katarina Sjögreen Gleisner   +8 more
doaj   +1 more source

Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE post-therapy whole body scintigraphy [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2020
We present the case of a 60-year-old man with metastatic neuroendocrine tumor of the ileum following ileal resection, being evaluated for 177Lu-based peptide receptor radionuclide therapy.
Ashwin Parihar, Apurva Sood, Ashwani Sood, Ajay Gulati, Bhagwant Mittal   +4 more
doaj   +1 more source

Farnesyltransferase Enables Modular Assembly of Dual‐Functional Nanobody Conjugates for in Vivo Imaging of Inflammation

Angewandte Chemie, EarlyView.
A modular farnesyltransferase‐based chemoenzymatic platform enables fast, site‐specific labeling of nanobodies for PET imaging of inflammation. CD11b‐targeted PET agents selectively image myeloid‐driven inflammation, while CD45‐targeted PET agents provide sensitive whole‐body immune mapping.
Sneha Venkatachalapathy, Yoon Ho Lee, Ali Salehi Farid, Heydar Moravej, Sina Djafari Rouhani, Jennifer E. Rowley, Mohammad Rashidian, Mark D. Distefano   +7 more
wiley   +2 more sources

Peptides in receptor-mediated radiotherapy : from design to the clinical application in cancers.

Frontiers in Oncology, 2013
Short peptides can show high affinity for specific receptors overexpressed on tumor cells. Some of these are already used in cancerology as diagnostic tools and others are in clinical trials for therapeutic applications. Therefore, peptides exhibit great
Catherine eLOZZA, Isabelle eTEULON, André ePELEGRIN, Jean-Pierre ePOUGET, Eric eVIVES   +4 more
doaj   +1 more source

Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy

EJNMMI Physics, 2022
Purpose To evaluate if satisfactory post-therapeutic image-based dosimetry can be achieved for Lu-177-DOTATATE treatments using a reduced number of image acquisitions to improve patient comfort and reduce economical costs.
Oscar Ardenfors, Joachim N. Nilsson, Daniel Thor, Cecilia Hindorf   +3 more
doaj   +1 more source